FierceBiotech 18 mar 2026 Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
FierceBiotech 18 mar 2026 JenaValve's Trilogy valve secures FDA's 1st approval in aortic regurgitation
FierceBiotech 17 mar 2026 Xaira exec divulges R&D focus, how $1B fundraise fuels AI-driven hunt for what the 'industry is hungriest for'
FierceBiotech 17 mar 2026 FDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings
FierceBiotech 17 mar 2026 Hitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30%
FierceBiotech 17 mar 2026 BioVie plans $20M IPO for spinout tasked with developing liver disease drug
FierceBiotech 17 mar 2026 R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment
FierceBiotech 17 mar 2026 Roche inks Nvidia deal to bolster AI factory, speed up drug and diagnostic development
FierceBiotech 16 mar 2026 Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years